BTIG initiated coverage of vTv Therapeutics (VTVT) with a Buy rating and $40 price target vTv is a clinical-stage biotech company developing oral drugs for metabolic and inflammatory diseases, the ...

Tv Therapeutics (VTVT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement ...